• 主页
  • 查找结果
  • Body Size, Bone Mineral Density, and Body Composition in Obese Women After Laparoscopic Sleeve Gastrectomy: A 1-Year Longitudinal Study.

Body Size, Bone Mineral Density, and Body Composition in Obese Women After Laparoscopic Sleeve Gastrectomy: A 1-Year Longitudinal Study.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2015-07-03)
P Adamczyk, M Bužga, P Holéczy, Z Švagera, P Zonča, H Sievänen, W Pluskiewicz
摘要

Changes in body weight, waist and hip circumferences, body composition, and skeletal status in women after bariatric surgery were evaluated. Thirty-six women [mean age 41.2 ± (SD) 9.5 years, weight 115.7±18.0 kg, and BMI 42.1±5.3 kg/m(2)] underwent laparoscopic sleeve gastrectomy. Bone mineral density (BMD) at lumbar spine, femoral neck, total hip, and total body, and body composition were evaluated at baseline and 3, 6, and 12 months after surgery.Weight, BMI, waist and hip circumferences decreased significantly. Total body bone mineral content (TBBMC) increased by 2.5±3.5%, and fat, lean body mass, total mass and fat-% decreased significantly by 38.9±12.0%, 15.4±5.9%, 26.5±8.1%, and 17.6±8.9%, respectively. Slight decreases in total body (0.6±2.2%) and spine (1.2±7.1%) BMD were not significant, whereas total hip and femoral neck BMD decreased significantly by 5.3±8.2%, and 6.2±7.0% (p<0.001). Change (Δ) in TBBMC correlated only with Δ in weight (r=0.38, p<0.05) whereas Δ in all other body composition parameters correlated significantly with Δ in body weight and circumferences (r=0.46-0.98). The Δ in BMD (except total body BMD) correlated significantly with Δ in body composition parameters (r=0.34-0.59). Baseline fat and lean content besides changes in body fat and lean mass accounted for bone changes. In conclusion, bone loss after bariatric surgery is related to post-operative changes in body composition, as well as to weight loss and decrease in waist and hip circumferences.

材料
货号
品牌
产品描述

Sigma-Aldrich
25-羟基维生素D2, ≥98.0% (HPLC)
Supelco
25-羟基维生素D3标准液 CRM 溶液, 100 μg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
25-羟基维生素D3 一水合物, ≥99.0% (HPLC)
Sigma-Aldrich
25-羟基胆钙化醇, ≥98% (HPLC)
Supelco
25-羟基维生素D2标准液 CRM 溶液, 50 μg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
25-羟基维生素 D3 溶液, 100 μg/mL in ethanol, 98% (CP)
Sigma-Aldrich
25-羟基维生素 D3 溶液, 50 μg/mL in ethanol, 98% (CP)
Sigma-Aldrich
25-羟基维生素D2 溶液, 100 μg/mL in ethanol, 98% (CP)
Sigma-Aldrich
25-羟基维生素D2 溶液, 50 μg/mL in ethanol, 98% (CP)
Sigma-Aldrich
25-羟基维生素D2 溶液, 5 μg/mL in ethanol, 98% (CP)
Supelco
25-羟基维生素D2标准液 CRM 溶液, 5 μg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
25-羟基维生素 D3 溶液, 5 μg/mL in ethanol, 98% (CP)
Supelco
25-羟基维生素D3标准液 CRM 溶液, 5 μg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。